TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
2.000
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
2.040
+0.040 (2.00%)
After-hours: Apr 2, 2026, 7:21 PM EDT
Company Description
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.
It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names.
The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TherapeuticsMD, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Marlan Walker |
Contact Details
Address: 951 Yamato Road, Suite 220 Boca Raton, Florida 33431 United States | |
| Phone | 561 961 1900 |
| Website | therapeuticsmd.com |
Stock Details
| Ticker Symbol | TXMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000025743 |
| CUSIP Number | 88338N206 |
| ISIN Number | US88338N2062 |
| Employer ID | 87-0233535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marlan D. Walker J.D. | Chief Executive Officer |
| Joseph A. Ziegler | Principal Financial and Accounting Officer |
| Douglas Steelman | Vice President of Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2026 | 10-K/A | [Amend] Annual report |
| Apr 1, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Jan 21, 2026 | 8-K | Current Report |
| Dec 16, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 3, 2025 | ARS | Filing |
| Nov 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |